Archives
Categories

HemaBlog™

It’s refreshing when a company really
connects with the community they’re providing treatment options for, which is
why today, I’m happy to spread the word about the new promotional campaign from
Aptevo, the makers of the factor IX treatment, IXINITY® [coagulation
factor IX (recombinant)]. 
 
Read below to get the story on how
people in the hemophilia B community inspired the campaign, plus see it for yourself at JustBIXperiences.com.


This is a paid public announcement from Aptevo and does not constitute an endorsement of products or services. When you click on the links in this blog entry, you will be directed to the IXINITY website. LA Kelley Communications always advises you to be a savvy consumer when contacting any company; do not reveal
identifying information against your will. 
 

Finding inspiration from familiar faces

As IXINITY marks its second anniversary
as a treatment option for those with hemophilia B, the people behind the
product are excited to start the next phase with a fresh new face. They didn’t
have to look very far, because who better to represent the close-knit
hemophilia B community and the company that cares about them than real people actually
using IXINITY? 

Introducing…

Just B: Because life is bigger than hemophilia
B, make it your IXperience™ with IXINITY.

Please see Important Safety Information for IXINITY below.

An idea that became an identity, inspired
by everyone who is redefining what it means to have hemophilia B by living life
on your own terms and Just B-ing yourself.
 
By sharing your experiences, your
expectations, and your aspirations, you’ve shown that, regardless of having
hemophilia or not, everyone deserves the chance to Just B.

Meet the first people to be featured
sharing their IXINITY stories (and see if there are any familiar faces from the
community that you recognize) at JustBIXperiences.com.

Plus, find out more about what it means
to Just B and get connected in the IXINITY Family Room on Facebook.

IXINITY INDICATIONS AND IMPORTANT SAFETY INFORMATION

What
is IXINITY®?
IXINITY [coagulation factor IX (recombinant)] is a medicine
used to replace clotting factor (factor IX) that is missing in adults and
children at least 12 years of age with hemophilia B. Hemophilia B is also
called congenital factor IX deficiency or Christmas disease. Hemophilia B is an
inherited bleeding disorder that prevents clotting. Your healthcare provider
may give you IXINITY to control and prevent bleeding episodes or when you have
surgery.
IXINITY is not indicated for induction of immune tolerance
in patients with hemophilia B.
IMPORTANT
SAFETY INFORMATION for IXINITY®

  • You
    should not use IXINITY if you are allergic to hamsters or any ingredients in IXINITY.
  • You
    should tell your healthcare provider if you have or have had medical problems,
    take any medicines, including prescription and non-prescription medicines, such
    as over-the-counter medicines, supplements, or herbal remedies, have any
    allergies, including allergies to hamsters, are nursing, are pregnant or
    planning to become pregnant, or have been told that you have inhibitors to
    factor IX.
  • You
    can experience an allergic reaction to IXINITY. Contact your healthcare
    provider or get emergency treatment right away if you develop a rash or hives,
    itching, tightness of the throat, chest pain, or tightness, difficulty
    breathing, lightheadedness, dizziness, nausea, or fainting.
  • Your
    body may form inhibitors to IXINITY. An inhibitor is part of the body’s defense
    system. If you develop inhibitors, it may prevent IXINITY from working
    properly. Consult with your healthcare provider to make sure you are carefully
    monitored with blood tests for development of inhibitors to IXINITY.
  • If
    you have risk factors for developing blood clots, the use of IXINITY may
    increase the risk of abnormal blood clots.
  • Call
    your healthcare provider right away about any side effects that bother you or
    do not go away, or if your bleeding does not stop after taking IXINITY.
  • The
    most common side effect that was reported with IXINITY during clinical trials
    was headache.
  • These
    are not all the side effects possible with IXINITY. You can ask your healthcare
    provider for information that is written for healthcare professionals.
For more information about IXINITY, please see full Prescribing Information,
including Important Patient Information.
 
You are encouraged to report side effects of prescription drugs to the
Food and Drug Administration. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Aptevo
BioTherapeutics LLC, Berwyn, PA 19312
IXINITY [coagulation factor IX
(recombinant)] and
any and all Aptevo
BioTherapeutics LLC brand, product, service and
feature names, logos, and slogans are trademarks or registered trademarks of Aptevo
BioTherapeutics LLC in the United States and/or
other countries.
©
2017 Aptevo BioTherapeutics. All rights reserved. CM-FIX-0159
ADVERTISEMENT